Neurocrine Biosciences

是其中之一......

• Russell 3000;
• TOB Iconic 10,000.

Neurocrine Biosciences 是一家在股票代码 NBIX (US) 下上市的公司。

Neurocrine Biosciences 在 2 个国家有直接业务。

他们在：

• 生物技术50%
• 药店50%

涉及Neurocrine Biosciences的并购和融资。

• Neurocrine Biosciences 已收购 Diurnal Group (公布2022十一月30号).

查看带有其 27 名主要高管的组织结构图

Neurocrine Biosciences 搜索最多的简介

• Kyle Gano, Chief Executive Officer
• Shalini Sharp, Director
• Stephen Sherwin, Director

高管在Neurocrine Biosciences变化

• Kevin Gorman, President, Chief Executive Officer and Director, 将于 202410月10 退休  (新闻发布的2024五月29号).
• Kyle Gano 曾任 Chief Business Development and Strategy Officer, 将于 202410月10 升职为 Chief Executive Officer  (新闻发布的2024五月29号).

创建提醒
跟踪 Neurocrine Biosciences 的高管变动

Neurocrine Biosciences 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。

Popular M&A news in 生物技术

• Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
• AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
• Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).

生物技术 行业的其他推荐联系人

• Scholar Rock 企业 Kristina Burow - Director
• UroGen 企业 Fred Cohen - Director
• Adaptimmune Therapeutics 企业 Ali Behbahani - Non-Executive Director

了解更多有关生物技术行业的信息 >

Neurocrine Biosciences 的最新新闻稿

• Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules | Neurocrine Biosciences
• Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia | Neurocrine Biosciences
• Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance | Neurocrine Biosciences
• Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results | Neurocrine Biosciences
• News & Media | neurocrine.com
• Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use | Neurocrine Biosciences
• Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit | Neurocrine Biosciences
• Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia | Neurocrine Biosciences
• Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference | Neurocrine Biosciences
• Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia | Neurocrine Biosciences
• View more press releases Close

关于 Neurocrine Biosciences 的社交媒体

• Neurocrine Biosciences 在 维基百科、谷歌新闻 和 雅虎财经
• Neurocrine Biosciences 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Kyle Gano

致电Neurocrine Biosciences，电话：+1 858...

查看组织结构图

Register to receive your alert

报告错误